Research and development of anti-Alzheimer's drugs: An analysis based on technology flows measured by patent citations

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 7, 2014, Pages 791-800

  Xu, Jiachen ^a   Kong, Xiangjun ^a   Qiu, Lan ^a   Geng, Xiaomei ^a   Hu, Yuanjia ^a   Wang, Yitao ^a  

^a China jack1987168 163com   (Macao)

Author keywords

Alzheimer's disease; Patent citation network; Research and development; Technology cluster; Technology flow

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; DATA BASE; DRUG MARKETING; HUMAN; PATENT; REVIEW; TECHNOLOGY; UNITED STATES; ANIMAL; FACTUAL DATABASE;

ALZHEIMER DISEASE; ANIMALS; DATABASES, FACTUAL; HUMANS; PATENTS AS TOPIC;

EID: 84903185308     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.915943     Document Type: Review

References (37)

1. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012;8(2):131-68
2. Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 2010;19(R1):R4-11
3. Fleming L. Recombinant uncertainty in technological search. Manage Sci 2001;47(1):117-32 (Pubitemid 34191966)
4. Jaffe AB, Trajtenberg M. International knowledge flows: evidence from patent citations. Econ Innov New Technol 1999;8(1-2):105-36
5. É rdi P, Makovi K, Somogyvári Z, et al. Prediction of emerging technologies based on analysis of the U.S. patent citation network. Scientometrics 2013;95(1):225-42
6. Stolpe M. Determinants of knowledge diffusion as evidenced in patent data: the case of liquid crystal display technology. Res Policy 2002;31(7):1181-98
7. Narin F. Patent bibliometrics. Scientometrics 1994;30(1):147-55
8. Karki M. Patent citation analysis: a policy analysis tool. World Pat Inf 1997;19(4):269-72 (Pubitemid 127167830)
9. Chang SB, Lai KK, Chang SM. Exploring technology diffusion and classification of business methods: using the patent citation network. Technol Forecast Soc 2009;76(1):107-17
10. Griliches Z. Patent statistics as economic indicators: a survey. J Econ Lit 1990;28(4):1661-707
11. Sorenson O, Rivkin JW, Fleming L. Complexity, networks and knowledge flow. Res Policy 2006;35(7):994-1017 (Pubitemid 44251135)
12. Choe H, Lee DH, Seo IW, et al. Patent citation network analysis for the domain of organic photovoltaic cells: country, institution, and technology field. Renew Sust Energ Rev 2013;26:492-505
13. Cho TS, Shih HY. Patent citation network analysis of core and emerging technologies in Taiwan: 1997-2008. Scientometrics 2011;89(3):795-811
14. Li X, Chen H, Huang Z, et al. Patent citation network in nanotechnology (1976-2004). J Nanopart Res 2007;9(3):337-52 (Pubitemid 46742857)
15. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010;9(7):702-16
16. Lukiw WJ. Amyloid beta (Ab) peptide modulators and other current treatment strategies for Alzheimer's disease (AD). Expert Opin Emerg Drugs 2012;17(1):43-60
17. Sabbagh MN. Drug development for Alzheimer's disease: where are we now and where are we headed? Am J Geriatr Pharmacother 2009;7(3):167-85
18. Misra S, Medh B. Drug development status for Alzheimer's disease: present scenario. Neurol Sci 2013;34(6):831-9
19. Lioyd M, Mokdsi G, Spielthenner D. Clearing the fog: patenting trends for the treatment of Alzheimer's disease. Pharm Pat Anal 2012;1(4):437-55
20. Hu YJ, Scherngell T, Man SN, et al. Is the United States still dominant in the global pharmaceutical innovation network? PLoS One 2013;8(11):e77247
21. Boccaletti S, Latora V, Moreno Y, et al. Complex networks: structure and dynamics. Phys Rep 2006;424(4-5):175-308 (Pubitemid 43135890)
22. Caldwell WS, Lippiello PM; inventors. R. J. Reynolds Tabacco Company, USA. Assignee Method for treatment of neurodegenerative diseases. US5212188; 1993
23. Gold M, Alderton C, Zvartau-Hind M, et al. Effects of rosiglitazone as monotherapy in APOE4-stratified subjects with mild-to-moderate Alzheimer's disease. Alzheimers Dement 2009;5(4):P86
24. Vellas B, Black R, Thal LJ, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009;6:144-51
25. Geels FW. Technological transitions as evolutionary reconfiguration processes: a multi-level perspective and a case-study. Res Policy 2002;31(8-9):1257-74
26. Harhoff D, Narin F, Scherer FM, et al. Citation frequency and the value of patented inventions. Rev Econ Stat 1999;81(3):511-15
27. Harhoff D, Scherer FM, Vopel K. Citations, family size, opposition and the value of patent rights. Res Policy 2003;32(8):1343-63
28. Trajtenberg M. A penny for your quotes: patent citations and the value of innovations. Rand J Econ 1990;21(1):172-87
29. Rosini M, Simoni E, Bartolini M, et al. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. J Med Chem 2008;51(15):4381-4
30. Simoni E, Daniele S, Bottegoni G, et al. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J Med Chem 2012;55(22):9708-21
31. Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008;51(3):347-72 (Pubitemid 351252260)
32. Chen X, Zenger K, Lupp A, et al. Tacrine-silibinin codrug shows neuroand hepato protective effects in vitro and pro-cognitive and hepatoprotective effects in vivo. J Med Chem 2012;55(11):5231-42
33. Luo Z, Sheng J, Sun Y, et al. Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen. J Med Chem 2013;56(22):9089-99
34. Belluti F, Rampa A, Gobbi S, et al. Small-molecule inhibitors/modulators of amyloid-beta peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010-2012). Expert Opin Ther Pat 2013;23(5):581-96
35. Chen YS, Chang KC. Using neural network to analyze the influence of the patent performance upon the market value of the US pharmaceutical companies. Scientometrics 2009;80(3):637-55
36. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4(11):682-90
37. Guo Y, Hu Y, Zheng M, et al. Patent indicators: a window to pharmaceutical market success. Expert Opin Ther Pat 2013;23(7):765-71